Alkeran 
Active substance: Melphalan
Manufacturer: GlaxoSmithKline
Extract from the prescribing information:
"Secondary malignancies, including acute nonlymphocytic leukemia, myeloproliferative syndrome, and carcinoma, have been reported in patients with cancer treated with alkylating agents (including Melphalan)."
"Patients should be informed that the major acute toxicities of melphalan are related to bone marrow suppression, hypersensitivity reactions, gastrointestinal toxicity, and pulmonary toxicity."
"Patients should never be allowed to take the drug without close medical supervision"
The above has been extracted from the Alkeran prescribing information on the GSK webpages.